It is prevalent that most companies want to make an immediate impact into the drug industry and for Actelion, it doesn’t want to waste time at all.
Focusing dearly on its experimental sleeping drug, Actelion wants to have a partner that will help focus on the sales and the market once it is ready to break into the market.
“Swiss biotech Actelion Ltd (ATLN.VX: Quote, Profile, Research) is looking for a partner to help with the eventual launch of its experimental sleep drug, its chief executive told Reuters on Thursday.
Actelion itself will run late-stage trials for almorexant, due to start this year, but a partner would help ramp up sales faster after launch, CEO Jean-Paul Clozel said in an interview. “
Source: Actelion eyeing partner for launch of sleep drug
More similar categories at Sleepzine: SLEEP News, Sleeping Pills.
